Shu-Fang Guo (Shufang Guo)

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Acute Lymphoblastic Leukemia

Multiple Myeloma

Prognostic Factors

Top Venues

Cancer gene therapy

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing-Ming Wang, Guang-Yu Lian, Su-Mei Sheng, Jing Xu, Long-Long Ye, Chao Min, Shu-Fang Guo
Exosomal lncRNA NEAT1 inhibits NK cell activity to promote multiple myeloma cell immune escape via an EZH2/PBX1 axis. Molecular cancer research : MCR (2023)